Zuranolone Schedule IV proposal and siloxane conditions

Summary#

• The Canada Gazette published two government notices: a set of conditions that let a specific siloxane chemical be made or imported under limits, and a Health Canada proposal to add the drug zuranolone to Schedule IV of the Controlled Drugs and Substances Act.
• The siloxane conditions came into force on January 27, 2026. The public comment period on scheduling zuranolone is open until April 18, 2026.

What it does#

• Ministerial Condition No. 22407 (under the Canadian Environmental Protection Act, 1999) permits the manufacture or import of the substance siloxanes and silicones, di‑Me, Me 3-(2-oxiranylmethoxy)propyl, Me 3,3,3-trifluoropropyl (CAS RN 3086114-77-1) but only if the named notifier follows specified rules. Key requirements include:

  • Immediate action and notification if the substance is accidentally released to the environment.
  • Written notice given to anyone receiving the substance and written confirmation that they agree to comply with the conditions before the first transfer.
  • Detailed record-keeping about uses, quantities, transfers and recipients, kept for at least 5 years and updated or created within 30 days in certain cases.
  • The conditions came into force on January 27, 2026.

• Health Canada is proposing to control zuranolone by adding it to Schedule IV of the Controlled Drugs and Substances Act. Practical effects if adopted would include:

  • Requirements for controlled-substance licences to produce, sell, transport, import or export zuranolone.
  • An import or export permit would be required for each shipment.
  • Researchers or clinical trials would need to apply for exemptions to work with the drug.
  • ZURZUVAE™, a prescription product containing zuranolone, was authorized in Canada on December 5, 2025; Health Canada says it would remain prescription-only if scheduled, and a transitional period for labelling changes is planned.
  • The consultation on this proposal is open until April 18, 2026.

Who's affected#

• For the siloxane conditions:

  • The company or person who filed the notification on December 12, 2025 (the “notifier”).
  • Any companies that manufacture, import, sell or receive this specific chemical in Canada.
  • Local enforcement officers and provincial/territorial 24-hour emergency contacts who would get release notifications.

• For the zuranolone proposal:

  • Health Canada (as the regulator) and companies that make, distribute or import zuranolone products.
  • Pharmacies, wholesalers and transporters that handle the drug.
  • Researchers and clinical trial sponsors who would need exemptions to study the drug.
  • Border and law-enforcement agencies that would enforce new import/export rules.
  • Patients prescribed ZURZUVAE™ — access would remain by prescription, but supply-chain and research rules could change.

Why it matters#

• The siloxane conditions add specific safety and paperwork rules for a chemical that the government suspects could be toxic. That affects businesses that work with it and provides a clearer emergency response process for accidental releases.
• Scheduling zuranolone would increase oversight to reduce the risk of misuse or illegal diversion. That means more licences, permits and paperwork for manufacturers, importers and researchers — but it would not remove prescription access for patients.
• The zuranolone item is a proposal. Public comments submitted by April 18, 2026 can influence the final regulatory decision.